Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review
Metrics: PDF 3795 views | HTML 1980 views | ?
Peisi Kou1,2,*, Yan Zhang2,*, Wenbo Shao4, Hui Zhu2, Jingze Zhang2, Haiyong Wang2, Li Kong2 and Jinming Yu2,3,1
1 Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
3 School of Medicine and Life Sciences, University of Jinan - Shandong Academy of Medical Sciences, Jinan, China
4 Department of Intervention, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
* These authors have contributed equally to this work
Jinming Yu, email:
Keywords: hepatocellular carcinoma, apatinib, targeted therapy
Received: September 06, 2016 Accepted: January 04, 2017 Published: January 18, 2017
Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. Previous studies have suggested that apatinib is safe and effective in some solid tumors. We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively. TACE was administered three times once a month, using lipiodol 10ml, oxaliplatin 150mg, and tegafur 1g. The dose of apatinib was 500 mg/d from day 4 to 24. After TACE, the patient received chemotherapy of regimen FOLFOX4, oxaliplatin intravenously at 85 mg/m2 on day 1, calcium levofolinate 200 mg/m2 on day 1 and 2, 5-fluorouracil 400 mg/m2 intravenously and 5-fluorouracil 600 mg/m2 intravenously pumped for 22h on day 1 and 2, cycled every two weeks for seven cycles. He took concurrently apatinib with a dose of 500mg daily from 1 to 10 days per cycle. He was confirmed as partial response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST). The level of serum alpha-fetoprotein (AFP) decreased from 60500 ng/ml to 12.7 ng/ml, and the progression free survival (PFS) time was more than eight months. It indicated that apatinib may be a superior choice for HCC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.